Celcuity (CELC) vs Parabilis Medicines (PBLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Parabilis Medicines is the larger company by market cap ($3.56 billion vs $3.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | PBLS |
|---|---|---|
| Share price | $65.78 | $28.82 |
| Market cap | $3.22B | $3.56B |
| 1-day change | -7.68% | -0.14% |
| YTD return | -34.05% | — |
| 1-year return | +33.66% | — |
| 5-year return | +261.43% | — |
| EPS (TTM) | $-4.31 | $-9.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-177.04M | — |
| 52-week high | $151.02 | $42.49 |
| 52-week low | $45.03 | $24.51 |
| Distance from 52-week high | -56.44% | -32.17% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +138.54% | +44.86% |
| Average volume | 1.18M | 670.37K |
| Shares outstanding | 48.93M | 121.95M |
| Employees | 155 | 145 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
CELC vs PBLS FAQ
Which is bigger, Celcuity or Parabilis Medicines?
Parabilis Medicines (PBLS) is larger, with a market capitalization of $3.56B compared with $3.22B for Celcuity (CELC).
Are Celcuity and Parabilis Medicines in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Celcuity and Biotechnology: Pharmaceutical Preparations for Parabilis Medicines.